ESMO 2021 | Updates from the PRISM study

Naveen S. Vasudev, BMSc (Hons), MBCHB, MRCP, PhD, The University of Leeds, Leeds, UK, shares an overview of the findings of the Phase II PRISM study assessing the safety of less frequent dosing of ipilimumab (modified schedule 12-weekly versus standard schedule 3-weekly) in combination with nivolumab in patients with untreated locally advanced or metastatic clear cell renal cell carcinoma (RCC). The study met its primary safety endpoint, with 33% of patients receiving ipilimumab 12-weekly experiencing grade 3-4 treatment-related toxicities in comparison to 53% in patients receiving ipilimumab every three weeks. In addition, the rates of treatment discontinuation due to adverse effects were also lower for patients in the modified schedule arm. Dr Vasudev explains that although the two arms cannot be formally compared, there doesn’t appear to be a decrease in efficacy for the patients that received ipilimumab every 12 weeks. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.